Previous Close | 6.97 |
Open | 6.90 |
Bid | 6.45 x 300 |
Ask | 6.49 x 100 |
Day's Range | 6.33 - 7.07 |
52 Week Range | 5.89 - 24.81 |
Volume | |
Avg. Volume | 1,324,496 |
Market Cap | 395.951M |
Beta (5Y Monthly) | 1.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Best Medical Stocks to Buy Under $10. The healthcare sector spans medical stocks including biotechnology companies, health insurance […]